Drug Profile
Research programme: antibacterials - Pfizer/Defense Threat Reduction Agency
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Anacor Pharmaceuticals
- Developer Anacor Pharmaceuticals; Colorado State University; University of California at Berkeley
- Class Organic boron compounds
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Bacterial-infections in USA
- 24 Jun 2016 Anacor Pharmaceuticals has been acquired by Pfizer
- 22 Oct 2013 Early research in Bacterial infections in USA (unspecified route)